Randomised feasibility study evaluating eye movement desensitisation and reprocessing therapy for functional neurological disorder (MODIFI) 2025 Cope+

Andy

Senior Member (Voting rights)
Abstract

Background
Functional neurological disorder (FND) is a common neurological presentation with symptoms such as seizures, walking difficulties, limb weakness and cognitive difficulties. Treatments for FND include physiotherapy and psychological therapy. Eye movement desensitisation and reprocessing therapy (EMDR) is a therapy designed to reduce disturbance associated with distressing or traumatic memories. Case report evidence suggests possible benefit for people with FND. This randomised feasibility study aimed to assess whether a large-scale trial evaluating EMDR for FND would be feasible and acceptable.

Methods
Fifty participants with FND were randomised to either FND-focused EMDR plus standard neuropsychiatric care (NPC) or NPC alone. Feasibility criteria were recruitment rate, intervention adherence, and outcome measure completion. Assessment of safety was also examined, as well as therapy satisfaction. Participants completed questionnaires at baseline, 3 months, 6 months and 9 months. FND symptoms were assessed using Ecological Momentary Assessment at each time point.

Results
Recruitment rate was 58%, intervention adherence was 88%, and outcome measure completion was 68% for Ecological Momentary Assessment and 76% for questionnaires at 9-month follow-up. Participants experienced functional motor symptoms (80%), functional seizures (64%), and cognitive symptoms (32%). Participants receiving EMDR + NPC reported greater satisfaction and greater FND improvement compared to NPC. Questionnaire data suggested greater reductions in PTSD, depression, anxiety, dissociation, disability and healthcare-use for EMDR + NPC.

Discussion
The study demonstrated that an FND-specific protocol for EMDR was feasible and acceptable. Potential positive effects on FND symptoms, mental health, disability, and healthcare utilisation were found. A full-scale trial is warranted to establish efficacy.

Open access

Thread on protocol here.
 
Recruitmenr started December 2022. They swapped the primary outcome in April 2023, from a PROMS to adherence and eligibility.
Old:
Primary Outcome Measures
  1. World Health Organisation Disability Assessment Schedule (WHODAS 2.0)
    Health-Related Quality of life/functioning measure
    [Time Frame: 9 months (trial period)]
New:
  1. Recruitment rate
    Percentage of potentially eligible participants attending screening interview
    [Time Frame: 12 months (recruitment stage)]
  2. Intervention adherence
    Percentage of participants randomised to EMDR+NPC who complete therapy
    [Time Frame: 18 months (intervention stage)]
  3. Outcome measures completion
    Percentage of participants who complete outcome measures at all 4 time points
    [Time Frame: 12 months (9-month follow-up stage)]
 
Those are terrible rates suggesting low acceptability and extremely low potential value. Especially when the premise is so absurd and unrelated to the problems. But nothing matters in this fake discipline, so, whatever.

It's actually a puzzle why they even bother doing feasibility studies. There is really no other explanation that makes sense other than that it produces more papers. All extremely low-quality, but this is something they consider acceptable, for reasons that will never make sense.
 
Back
Top Bottom